Skip to main content

Cepheid Shares Up 8.4 Percent on Anthrax Detection News

NEW YORK, Feb. 16 (GenomeWeb News) - Shares of Cepheid were up $.80, or 8.41 percent, at $10.31 in afternoon trading after the company this morning said that its GeneXpert real-time PCR platform for mobile anthrax detection had been licensed by biothreat agencies in Oakland, Mich., and Honolulu, Hawaii.

The Scan

Response Too Slow, Cautious

A new report criticizes the global response to the threat of the COVID-19 pandemic, Nature News reports.

Pushed a Bit Later

Novavax has pushed back its timeline for filing for authorization for its SARS-CoV-2 vaccine, according to Bloomberg.

AMA Announces Anti-Racism Effort

The Associated Press reports that the American Medical Association has released a plan to address systemic racism in healthcare.

Nucleic Acids Research Papers on miRMaster 2.0, MutationTaster2021, LipidSuite

In Nucleic Acids Research this week: tool to examine small non-coding RNAs, approach to predict ramifications of DNA variants, and more.